Alcresta Therapeutics Email Formats
Medical Equipment Manufacturing • 
Newton, Massachusetts, United States • 51-100 Employees
Alcresta Therapeutics Email Formats
Alcresta Therapeutics uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@alcresta.com), used 74.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@alcresta.com | 74.6% |
{first initial}{last name} | jdoe@alcresta.com | 23.8% |
{first initial} | j@alcresta.com | 1.6% |
Key Contacts at Alcresta Therapeutics
Corey Starke
Senior Director, Commercial Operations
Eric Mccord
Associate Director, Commercial Strategy & Analytics
Ernest Waaser
Board Of Directors
Jennifer Blakely
Senior Director Human Resources
Lynn Wilson
Director Clinical Development
Jim Kevil
Sr. Director, Finance
Anne Smith
Executive Assistant To Chairman And Chief Executive Officer
Rookmin Persaud
Associate Director, Regulatory Affairs
David O'Carroll
Director Of Quality
Christina Mastandrea
Sr. Director, Clinical Operations
Company overview
| Headquarters | One Newton Executive Park, Suite 100, Newton, MA 02462, US |
| Phone number | +105635747 |
| Website | |
| NAICS | 3391 |
| SIC | 873 |
| Founded | 2011 |
| Employees | 51-100 |
| Socials |
About Alcresta Therapeutics
Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by Linden Capital Partners and HealthQuest Capital.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Alcresta Therapeutics has 50 employees across 12 departments.
Departments
Number of employees
Alcresta Therapeutics Tech Stack
Discover the technologies and tools that power Alcresta Therapeutics's digital infrastructure, from frameworks to analytics platforms.
CDN
Security
JavaScript libraries
Tag managers
Webmail
Miscellaneous
Miscellaneous
Miscellaneous
UI frameworks
Analytics
United Kingdom
India
France
Frequently asked questions
4.8
40,000 users
